× Key messages Background Findings Perspectives Expert commentary
Go back | list
format_size dark_mode
icon-previous icon-next

Pharmacokinetic and safety evaluation of multiple lasmiditan dosage

Key messages

  • Lasmiditan is a novel, highly selective, potent serotonin (5-HT)1F receptor agonist, approved in the United States for the acute treatment of adult migraine with or without aura.
  • Repeat doses of lasmiditan do not present any new safety issues and are well tolerated.
  • There is no accumulation of lasmiditan with daily dosing due to its short half-life.
  • Although in-vitro data suggested lasmiditan may induce some cytochrome P450 (CYP) enzymes, the in-vivo results have not shown this to be the case.